Ceftriaxone is not used in the treatment of MRSA because it is a cephalosporin antibiotic that does not have activity against methicillin-resistant Staphylococcus aureus (MRSA). MRSA is resistant to beta-lactam antibiotics, such as cephalosporins, due to the production of a penicillin-binding protein that has a low affinity for these antibiotics.

On the other hand, vancomycin and teicoplanin are glycopeptide antibiotics that are commonly used to treat MRSA infections. These antibiotics are effective against a wide range of gram-positive bacteria, including MRSA.

Rifampicin and doxycycline are also used in the treatment of MRSA infections, although they may not be the first-line choices. Rifampicin is a rifamycin antibiotic that is often used in combination with other antibiotics to treat MRSA infections. Doxycycline is a tetracycline antibiotic that can be used for less severe MRSA infections or as part of combination therapy.

In summary, ceftriaxone is not used in the treatment of MRSA, while vancomycin, teicoplanin, rifampicin, and doxycycline are all potential treatment options for MRSA infections.

All of the organisms listed above can cause pneumonia in immunocompromised individuals but the most likely cause in this patient is Pneumocystis jirovecii.

It is a leading AIDS-defining infection in HIV-infected individuals and causes opportunistic infection in immunocompromised individuals. HIV patients with a CD4 count less than 200 cells/mm3 are more prone.

The clinical features of pneumonia caused by Pneumocystis jirovecii are:
Fever, chest pain, cough (usually non-productive), exertional dyspnoea, tachypnoea, crackles and wheeze.
Desaturation on exertion is a very sensitive sign of Pneumocystis jirovecii pneumonia.

Chest X-ray can show perihilar fluffy shadowing (as is seen in this case) but can also be normal.

ART initiation is a complex process that requires specialized training and knowledge in HIV treatment and management. NIMART (Nurse-Initiated Management of Antiretroviral Treatment) trained nurses and doctors have received specific training in initiating and managing ART for patients with HIV. They have the necessary skills to assess a patient’s eligibility for ART, prescribe the appropriate medications, monitor treatment progress, and manage any potential side effects or complications.

General physicians, community health workers, pharmacists, and social workers may also play important roles in supporting patients throughout their HIV treatment journey, but the primary responsibility for ART initiation typically falls on NIMART trained nurses or doctors. Their specialized training and expertise make them well-equipped to provide high-quality care and ensure the best possible outcomes for patients starting ART.

The 3-year-old boy presented with sudden onset pyrexia, emesis, and bilateral facial swelling, which are classic symptoms of mumps. Mumps is a viral infection that commonly affects the salivary glands, causing swelling and pain. The mother mentioned that the GP had already suggested analgesics for the parotid pain, which is a common symptom of mumps.

In the case of mumps, the treatment is usually supportive and focused on symptom management. Antibiotics are not effective against viral infections like mumps, so they would not be indicated in this case. Biopsy and immediate surgery are not necessary for the management of mumps, as it is a self-limiting condition that typically resolves on its own with time.

Therefore, the next step in the management of this 3-year-old boy with suspected mumps would be to offer reassurance to the mother. Reassurance can help alleviate any concerns she may have about her son’s condition and provide her with information on how to manage his symptoms at home.

Epithelioid cells are a type of macrophage that have enlarged and flattened out, resembling epithelial cells. In the context of tuberculosis, these cells are found in granulomas, which are structures formed by the immune system in response to the infection. The presence of epithelioid cells in a cervical biopsy from a patient with tuberculosis indicates the formation of granulomas in the tissue as part of the body’s defense mechanism against the infection. This finding is important for diagnosing tuberculosis and monitoring the progression of the disease.

When an HIV-positive individual is receiving rifampicin-containing TB treatment, there is a potential for drug interactions with certain antiretroviral drugs. Rifampicin is known to induce the metabolism of many antiretroviral drugs, leading to decreased levels of these medications in the body. This can result in reduced efficacy of the antiretroviral treatment and potentially lead to treatment failure.

Dolutegravir (DTG) is one of the antiretroviral drugs that requires dose adjustment when co-administered with rifampicin. DTG is a integrase inhibitor that is commonly used in HIV treatment regimens due to its potency and tolerability. However, when taken with rifampicin, the metabolism of DTG is increased, leading to lower drug levels in the body.

To counteract this effect and maintain optimal antiviral efficacy, the standard dose of DTG needs to be increased when taken with rifampicin-containing TB treatment. This adjustment helps to ensure that sufficient levels of DTG are maintained in the body to effectively suppress HIV replication.

In the context of ART management, a dispensing cycle (DC) refers to the number of days for which a client receives treatment in a single standard monthly dosage. This means that if a client is prescribed a certain number of tablets to last them for a month, the dispensing cycle would be the number of days covered by that quantity of tablets.

The other options provided in the question do not accurately define a dispensing cycle in the context of ART management. The number of clinic visits per month, the time between two viral load tests, the interval between the initiation and the first revision of the ART regimen, and the waiting period for ART initiation after HIV diagnosis are all important aspects of ART management, but they do not specifically relate to the concept of a dispensing cycle.

When a client on TLD (tenofovir/lamivudine/dolutegravir) for at least 2 years has a persistent non-suppressed viral load, it is important for clinicians to address this issue promptly. The first step should be to provide enhanced adherence counseling (EAC) to ensure the client is taking their medication as prescribed. If adherence is confirmed to be above 80%, resistance testing may be considered to determine if there is any drug resistance that is contributing to the lack of viral suppression.

Switching to a non-DTG-containing regimen without further tests is not recommended as it may not address the underlying issue causing the non-suppressed viral load. Discontinuing ART treatment entirely is also not recommended as it can lead to a resurgence of the virus and potential harm to the client’s health. Increasing the dosage of TLD or switching to a regimen containing only NRTIs may not be effective in achieving viral suppression if there is underlying drug resistance.

Therefore, the best course of action is to provide EAC and consider resistance testing if adherence is confirmed to be above 80%. This approach allows clinicians to address potential adherence issues and identify any drug resistance that may be contributing to the non-suppressed viral load, leading to more effective management of the client’s HIV treatment.

Opportunistic infections are infections that occur more frequently or are more severe in individuals with weakened immune systems, such as those with AIDS. Pneumocystis jirovecii pneumonia is a type of pneumonia caused by a fungus that can be life-threatening in individuals with compromised immune systems, particularly those with AIDS. This infection is commonly associated with AIDS because the weakened immune system is unable to effectively fight off the fungus, leading to severe respiratory symptoms and potentially fatal complications. It is important for individuals with AIDS to receive proper medical care and treatment to prevent and manage opportunistic infections like Pneumocystis jirovecii pneumonia.

Primary syphilis is the initial stage of syphilis infection and is characterized by the presence of a painless, firm, ulcerated lesion known as a chancre. This lesion is typically found on the genitals, including the cervix in women, and is caused by the bacterium Treponema pallidum.

In this case, the lady was found to have a 12mm ulcerated, indurated lesion on her cervix during a speculum examination. Since she was otherwise asymptomatic and the lesion was painless, the most likely cause would be Treponema pallidum, the organism responsible for syphilis.

Other options such as Herpes Simplex Type 1 and Type 2, Neisseria gonorrhoeae, and Chlamydia Trachomatis D-K are not typically associated with the development of a painless ulcerated lesion like the one described in the scenario. Therefore, the most appropriate answer is Treponema pallidum.

Before a client initiates antiretroviral therapy (ART) for HIV, it is crucial to confirm their HIV status through laboratory testing. This is important because ART is a lifelong commitment and has potential side effects, so it is essential to ensure that the client actually has HIV before starting treatment.

The laboratory evaluation routinely performed to confirm HIV status before initiating ART includes a Confirm HIV test result. This test is typically a more specific and sensitive test than the initial screening test, providing a more accurate diagnosis.

In addition to the Confirm HIV test result, other laboratory evaluations may also be performed before starting ART. These may include a CD4 cell count or percentage, which helps determine the strength of the client’s immune system, as well as tests for creatinine and estimated glomerular filtration rate (eGFR) if tenofovir disoproxil fumarate (TDF) is going to be used in the ART regimen. Haemoglobin levels may also be checked to assess for anemia, which is common in individuals with HIV.

Overall, confirming HIV status through laboratory testing before initiating ART is essential to ensure that the client receives the appropriate treatment and monitoring for their condition.

Repeat viral load testing is an important aspect of monitoring HIV treatment effectiveness in clients. The range of viral load considered for clients with repeat testing helps healthcare providers determine the level of viral replication in the body and assess the response to antiretroviral therapy.

A viral load of < 10 c/mL is considered undetectable and indicates successful suppression of the virus. This is the ideal outcome for clients on HIV treatment. A viral load of 10-49 c/mL is still considered low and may not necessarily indicate treatment failure, but it does warrant closer monitoring. A viral load of 50-999 c/mL falls within the range of persistent low-grade viremia. This level of viral replication may indicate suboptimal adherence to treatment or the development of drug resistance. Clients in this range require careful monitoring and potential interventions to address any issues that may be affecting treatment efficacy. A viral load of ≥ 1000 c/mL is considered high and indicates treatment failure. This level of viral replication may lead to disease progression and the development of complications. Clients with a viral load in this range may need to switch to a different antiretroviral regimen to achieve viral suppression. Therefore, the correct answer to the question is 50-999 c/mL, as clients falling within this range on repeat viral load testing are categorized as having persistent low-grade viremia and require closer monitoring and potential interventions to optimize treatment adherence and efficacy.

Human papillomavirus (HPV) is a common sexually transmitted infection that can lead to the development of various cancers, including cervical cancer. The onco-proteins associated with HPV infection are E6 and E7. These onco-proteins play a crucial role in the development of cancer by inactivating tumor suppressor proteins.

E6 oncoprotein is responsible for inactivating the p53 tumor suppressor protein, which plays a key role in regulating cell growth and preventing the formation of tumors. By inactivating p53, E6 allows infected cells to continue to divide uncontrollably, leading to the development of cancer.

E7 oncoprotein, on the other hand, inactivates the pRb tumor suppressor protein, which also helps regulate cell growth and division. By inactivating pRb, E7 allows infected cells to bypass normal cell cycle control mechanisms, leading to uncontrolled cell growth and the development of cancer.

Therefore, the correct answer to the question is E6 and E7, as these onco-proteins are directly involved in the development of HPV-related cancers by inactivating important tumor suppressor proteins.

When a birth PCR result is indeterminate, it means that the test did not provide a clear result regarding the presence or absence of HIV in the newborn. In this case, the next step according to PMTCT guidelines is to initiate prophylactic treatment without repeating the PCR test. This is because it is important to start treatment as soon as possible to reduce the risk of HIV transmission from mother to child.

Initiating prophylactic treatment, such as starting Bactrim at 6 weeks of life, can help prevent opportunistic infections in the newborn while further testing is conducted to confirm the HIV status. It is crucial to follow the PMTCT guidelines and provide appropriate care and treatment to ensure the health and well-being of the newborn. Waiting until the baby is 6 months old to redo the test or repeating the PCR in two weeks may delay necessary treatment and put the baby at risk of HIV transmission.

When an HIV-positive individual is receiving rifampicin-containing TB treatment, there is a potential for drug interactions with certain antiretroviral medications used to treat HIV. Rifampicin is known to induce the metabolism of many drugs, including antiretrovirals, which can lead to decreased levels of the antiretroviral medications in the body.

Dolutegravir (DTG) is one of the antiretroviral medications that requires dose adjustment when taken with rifampicin. Rifampicin can significantly reduce the levels of DTG in the body, potentially leading to reduced effectiveness of the HIV treatment. Therefore, it is important to adjust the dose of DTG when it is co-administered with rifampicin to ensure that adequate levels of the medication are maintained in the body to effectively suppress the HIV virus.

In contrast, medications like Lamivudine (3TC), Efavirenz (EFV), Zidovudine (AZT), and Atazanavir (ATV) do not require dose adjustments when taken with rifampicin-containing TB treatment. It is always important for healthcare providers to carefully consider potential drug interactions and adjust medication doses as needed to ensure optimal treatment outcomes for individuals with HIV and TB co-infection.

Creutzfeldt–Jakob disease = consuming beef or beef products.
Brucellosis = ingestion of unpasteurized milk or undercooked meat from infected animals.
Leptospirosis is transmitted by both wild and domestic animals. The most common animals that spread the disease are rodents.
Lyme disease is transmitted to humans by the bite of infected ticks of the Ixodes genus.
Leishmaniasis is a disease caused by protozoan parasites of the genus Leishmania and spread by the bite of certain types of sandflies.

Among people living with HIV in 2021, approximately 85% knew their HIV status according to WHO estimates.

The reason for switching a pregnant woman on EFV-based ART to a DTG-based regimen after counseling and confirming a viral load of <50 c/ml in the last six months is due to the potential risks associated with EFV during pregnancy. EFV has been associated with an increased risk of neural tube defects in the fetus, particularly when taken in the first trimester of pregnancy. DTG, on the other hand, has shown to be safe and effective in pregnancy with no increased risk of birth defects. Therefore, it is recommended to switch to a DTG-based regimen in order to minimize the potential risks to the fetus. Counseling is important to ensure that the woman understands the reasons for the switch and is informed about the potential benefits and risks of the new regimen. Additionally, confirming a viral load of <50 c/ml ensures that the woman's HIV is well-controlled before making the switch, which is important for both her health and the health of the fetus.

HIV weakens the immune system, making individuals more susceptible to infections. Live attenuated vaccines, such as the MMR vaccine, contain a weakened form of the virus that could potentially cause harm to individuals with compromised immune systems. Therefore, it is not recommended to give the MMR vaccine to a 12-month-old baby with HIV.

The most appropriate action in this scenario would be to not give the vaccine. It is important to consult with a healthcare provider to discuss alternative vaccination options for the baby. Deferment of the immunization for 2 weeks may not be sufficient, as live attenuated vaccines should generally be avoided in HIV+ patients. Giving a half dose of the vaccine or administering paracetamol with future doses of the same vaccine are not appropriate actions in this case.

It is crucial to prioritize the health and safety of the baby with HIV by following the recommended guidelines for vaccination in individuals with compromised immune systems. Consulting with a healthcare provider who is knowledgeable about the specific needs of HIV+ patients is essential in making informed decisions regarding vaccination.

The 28-year-old male likely has Lyme disease, which is a bacterial infection transmitted through the bite of an infected tick. The characteristic rash of Lyme disease is an annular rash known as erythema migrans. The drug of choice for treating Lyme disease, especially in the early stages when the rash appears, is doxycycline. Doxycycline is a tetracycline antibiotic that is effective against the bacteria responsible for Lyme disease. Penicillin, flucloxacillin, gentamicin, and ciprofloxacin are not typically used to treat Lyme disease. Therefore, the correct answer is Doxycycline PO.

Oral Candidiasis and its Association with Immune System Defects

Oral candidiasis, a fungal infection in the mouth, is a concerning condition in young healthy individuals as it may indicate an underlying defect in the immune system. Further investigation is necessary to identify the root cause of the infection. In London, men who have sex with men have a high prevalence of HIV, which is a likely diagnosis in such cases. HIV weakens the immune system, making individuals more susceptible to infections and other health complications.

Apart from HIV, other immune system defects may also lead to oral candidiasis. Recurrent attacks of shingles in a young person may also indicate a weakened immune system. Additionally, HIV infection is a predisposing factor for deep vein thrombosis (DVT), a condition where blood clots form in the veins deep within the body. Therefore, it is crucial to investigate the underlying cause of oral candidiasis and other related conditions to ensure timely diagnosis and appropriate treatment.

Overall, oral candidiasis is a red flag for immune system defects, and healthcare professionals should be vigilant in identifying and addressing the root cause of the infection.

When a client presents with symptoms of tuberculosis (TB), it is important to first confirm whether or not they actually have TB before initiating antiretroviral therapy (ART). This is because starting ART in a client with active TB can potentially worsen their condition due to immune reconstitution inflammatory syndrome (IRIS).

Therefore, it is recommended to defer ART initiation for clients diagnosed with TB symptoms until TB is excluded. This can be done through various diagnostic tests such as a TB GeneXpert test, sputum smear microscopy, or culture. Once TB is definitively ruled out, ART can be safely initiated without the risk of exacerbating the TB infection.

It is crucial to follow this protocol to ensure the best possible outcomes for clients with both TB and HIV, as well as to prevent any potential complications that may arise from starting ART prematurely in a client with active TB.

In young individuals with HIV infection, neuropathological findings such as lymphocytic leptomeningitis, perivascular lymphocytic cuffing, parenchymal T and B lymphocyte infiltration, and microglial activation are commonly observed. These findings are indicative of the inflammatory response and immune cell infiltration in the brain due to HIV infection.

However, axonal damage is a neuropathological finding that is not specific to HIV infection and can also be seen in the brains of drug users who do not have HIV. Axonal damage can result from various factors such as inflammation, trauma, and hypoxia, which are common in drug users. Therefore, the presence of axonal damage in both individuals with early HIV infection and drug users without HIV suggests that this particular neuropathological finding may not be specific to HIV infection but rather a result of other factors.

PrePex Device Offers Painless Male Circumcision for HIV Prevention

The PrePex device is a new method of male circumcision that is painless, sutureless, and does not require anaesthesia. It has been approved in countries such as Rwanda and is currently only available in sub-Saharan Africa. The World Health Organization (WHO) has found scientific evidence that male circumcision can significantly reduce the risk of HIV transmission. As a result, WHO is promoting this strategy in sub-Saharan Africa, where there has been a significant increase in the number of circumcision operations. However, it is important to note that circumcision should be used in conjunction with other measures, such as condom use, to reduce the incidence of HIV infection. The PrePex device is not designed for any other purposes.

Tuberculosis (TB) is a bacterial infection that primarily affects the lungs but can also affect other parts of the body. Common symptoms of TB in adults and adolescents include a persistent cough of 2 weeks or more, fever for more than two weeks, drenching night sweats, chest pain and discomfort, and unexplained weight loss.

Unexplained weight gain is NOT a common symptom of tuberculosis. In fact, unexplained weight loss is more commonly associated with TB as the infection can cause a loss of appetite and difficulty in absorbing nutrients from food. Weight gain is not typically seen in individuals with TB unless they are actively trying to gain weight through diet and exercise.

Therefore, the correct answer is: Unexplained weight gain.

As the immune response is activated, the virus is slowly cleared from the system, and most patients become non-infectious. In adults, about 50% of infections are asymptomatic; 20% to 30% of patients exhibit clinical jaundice but have a benign resolution of the infection. Therefore, about 80% of infections do not cause serious sequelae. The risk for chronic infection is inversely proportional to age at time of infection, with approximately 90% of infants and only 3% of adults developing a chronic infection.
Individuals with a chronic infection have a higher risk of liver disease, such as cirrhosis or hepatic carcinoma.

The preferred regimen for women of childbearing potential who are not actively trying to conceive is TLD (tenofovir, lamivudine, dolutegravir) because it is considered safe and effective for both the woman and any potential fetus in case of an unplanned pregnancy. TLD has a low risk of teratogenicity and is generally well-tolerated, making it a suitable option for women who may become pregnant. Additionally, dolutegravir has been shown to have a high barrier to resistance and is recommended as a first-line treatment for HIV.

Other regimens, such as EFV (efavirenz) or LPV/r (lopinavir/ritonavir), may have potential risks during pregnancy or may not be as effective in preventing transmission of HIV to the fetus. Therefore, TLD is the preferred choice for women of childbearing potential who are not actively trying to conceive according to the guidelines.

It is important for patients to adhere to their ARV drug regimen in order to effectively manage their HIV infection. However, some patients may have difficulty swallowing whole tablets, which can make it challenging for them to take their medication as prescribed. In such cases, it is recommended to crush, split, or open capsules/tablets as necessary and as specified for certain drugs.

Forcing the patient to swallow whole tablets regardless of their ability can lead to non-adherence and potentially compromise the effectiveness of the treatment. Discontinuing the ARV medication or switching to an entirely new regimen may not be necessary if the issue can be resolved by modifying the administration of the medication.

The guidelines provide specific advice on whether ARV tablets/capsules can be split, crushed, or opened if a patient is unable to swallow them whole. This allows healthcare providers to ensure that patients can continue their treatment while addressing any difficulties they may have with swallowing whole tablets. By following these recommendations, patients can maintain adherence to their ARV drug regimen and effectively manage their HIV infection.

Benzathine penicillin G is a type of antibiotic that is commonly used to treat bacterial infections. One of the common side effects of this medication is injection site pain and swelling. This occurs because the medication is administered via injection, which can cause discomfort and inflammation at the site of injection.

Nausea and vomiting, rash and itching, renal failure, and anaphylaxis are also potential side effects of Benzathine penicillin G administration, but they are less common than injection site pain and swelling. Nausea and vomiting may occur due to the medication’s effects on the gastrointestinal system, while rash and itching may be a sign of an allergic reaction. Renal failure is a rare but serious side effect that can occur in some individuals. Anaphylaxis is a severe allergic reaction that can be life-threatening and requires immediate medical attention.

Overall, it is important to be aware of the potential side effects of Benzathine penicillin G and to seek medical help if any concerning symptoms occur after administration.

HIV is a virus that attacks the immune system, specifically the CD4 cells (T cells) which are crucial in fighting off infections. As the virus progresses, the CD4 count decreases, making the individual more susceptible to infections and other complications.

AIDS (Acquired Immunodeficiency Syndrome) is diagnosed when the CD4 count drops below 200 cells/mm3. This is a critical point where the immune system is severely compromised, and the individual is at high risk for opportunistic infections and other complications.

Treatment with antiretroviral therapy is recommended when the CD4 count drops below 350 cells/mm3, as this helps to suppress the virus and prevent further damage to the immune system.